Navigation Links
Phase 3 data show viral cure rates achieved in a broad range of patients with genotype-1 hepatitis C taking investigational compound faldaprevir plus PegIFN/RBV
Date:11/2/2013

ymerase inhibitor that has shown the potential to eliminate interferon from HCV treatment when combined in a regimen with faldaprevir and RBV. Phase 2 trials of this interferon-free regimen have been completed and Phase 3 HCVerso® trials investigating this regimen are now underway. As part of our long-term commitment to HCV, the company is exploring other combinations of investigational HCV compounds that work in complementary ways. The recent collaboration of Boehringer Ingelheim with Presidio Pharmaceuticals, Inc. for a Phase 2a clinical study investigating an interferon- and ribavirin-free, all-oral combination is part of the company's continued commitment to discover and develop innovative options for the treatment of HCV.

STARTVerso™ and HCVerso® are registered service marks of Boehringer Ingelheim International GmbH.

The Liver Meeting® is a registered trademark of the American Association for the Study of Liver Diseases (AASLD).

Hepatitis C is a blood-borne infectious disease and a leading cause of chronic liver disease, transplant and failure that affects as many as 150 million people globally. In the United States, approximately 3.2-5.2 million people have chronic HCV infection. Since 1999 there has been a significant increase in deaths due to chronic HCV, which accounts for 10,000-12,000 deaths in the United States per year.

About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more th
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Relmada Therapeutics, Inc., ... the treatment of chronic pain, announced today that it ... the position of  Senior Director of Clinical Development. ... James has established and led successful global clinical operations ... , to facilitate the clinical development of numerous therapeutics ...
(Date:9/18/2014)... , Sept. 18, 2014 /CNW/ - A new expert panel ... Canada , released today by the Council ... and effective medicines for children. Each year about half ... use at least one prescription drug. Much of this ... the authorized use), creating potential health risks. ...
(Date:9/18/2014)... MARLBOROUGH, Mass. , Sept. 18, 2014 ... RXII ), a biotechnology company focused on ... major unmet medical needs using RNA-targeted technologies, ... Executive Officer, Dr. Geert Cauwenbergh , ... Annual BioPharm America™ Conference on Wednesday, September ...
Breaking Medicine Technology:Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
... of evaluable heavily-pretreated patients in the high dose ... tolerated overall.DALLAS, March 5 ACCESS PHARMACEUTICALS, ... safety and efficacy results from its Phase 2 ... heavily pretreated ovarian cancer patients. In this monotherapy ...
... March 4 A new study by researchers at ... essential B vitamins, including B6, B12, and folic acid, ... of the leading causes of vision loss among older ... key omega-3 fatty acids and phytosterols, are also contained ...
Cached Medicine Technology:Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 2Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 3Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results 4Harvard Study Shows Folic Acid, B Vitamins in Animi-3(R) May Prevent Vision Loss 2
(Date:9/18/2014)... has proven it true: exercise is good for you. ... that exercise may have an added benefit for cancer ... mouse model of melanoma, found that combining exercise with ... Joseph Libonati, an associate professor in the School of ... Translational Nursing Research, was the senior author on the ...
(Date:9/18/2014)... 18, 2014 TayganPoint Consulting Group, ... that President and co-founder John Cassimatis was named ... Winners for 2014, recognizing the region’s top healthcare ... emerging executive of the year. , The Innovation ... sciences that continue to shape the medical industry ...
(Date:9/18/2014)... 2014 Ben Quirk, CEO of Quirk ... Leadership Award by the Savannah Science Seminar in recognition ... throughout the nation and especially in Savannah. , “I ... Ben. “The Savannah Science Seminar is an amazing program ... generations have gone through the program,” he added. Eleventh ...
(Date:9/18/2014)... developed a new method to study Ebola virus in ... Conservation Society (WCS)-led research, published today in the journal ... of fecal samples from wild great apes to identify ... This represents a new tool for performing large, population-scale ... virus is studied and improve our understanding of the ...
(Date:9/18/2014)... The National Institutes of Health (NIH) recently awarded ... million grant to the Los Angeles Biomedical Research Institute ... of a vaccine to protect patients from the healthcare-related ... (MRSA). , The National Institute of Allergy ... grant to LA BioMed infectious disease specialists John E. ...
Breaking Medicine News(10 mins):Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... A group of Northeast Ohio breast,cancer survivors continue to ... the disease by participating in the sport of Dragon ... canoeing, involves a team of 22,paddlers racing in 40-foot-long ... the team offers women living with breast cancer an,opportunity ...
... Increasing temperatures, carbon dioxide levels add to discomfort of ... Add increased suffering for people with ragweed allergies to ... new study suggests. , Recent research indicates that ... longer ragweed seasons and more concentrated pollen counts, says ...
... certain genotype more affected, study finds , , MONDAY, Aug. ... containing codeine may be unwittingly risking the health of ... indicates that a relatively rare genetic predisposition causes some ... than normal -- possibly harming the infant,s central nervous ...
... at menopause as well as a woman,s breastfeeding practices ... breast cancer. That was the conclusion of a new ... CANCER, a peer-reviewed journal of the American ... distinct and separate hormonal risk factors associated with different ...
... Bikes Belong and Humana, launches Freewheelin ... bike-sharing initiative ... Inaugural Ride, DENVER, Aug. 24 Bike-sharing officially,rolled into Denver ... date: Freewheelin. Leading 100 cyclists,through the streets of Denver, Mayor Hickenlooper ...
... Benefit Group, LLC announces iCan Insurance, LLC ("iCan Insurance", "iCan") ... Inc. , ... Boca Raton, FL ... iCan Insurance, LLC ("iCan Insurance", "iCan") is now offering major ...
Cached Medicine News:Health News:Dragon Dream Team Continues to Send Message of Hope a Year Later 2Health News:Climate Change Linked to Longer Pollen Seasons 2Health News:Taking Codeine While Breast-Feeding May Harm Infant 2Health News:Taking Codeine While Breast-Feeding May Harm Infant 3Health News:Breastfeeding, other factors may affect risk of breast cancer type 2Health News:Kicking Into High Gear: Nation's Largest Bike-Sharing Program Debuts at Democratic National Convention 2Health News:Kicking Into High Gear: Nation's Largest Bike-Sharing Program Debuts at Democratic National Convention 3Health News:Kicking Into High Gear: Nation's Largest Bike-Sharing Program Debuts at Democratic National Convention 4Health News:iCan Benefit Group, LLC Announces: Major Medical Division Now Offers Avalon Healthcare Products 2
Large image and wide angle design for transurethral examination and treatment of the ureter and renal pelvis....
High intensity lamp with built-in, switchable spare lamp. Low-noise fan with reduced air turbulence....
Calculate accurate growth percentiles and Z scores using the latest CDC growth charts....
PDA-version of the leading portable drug reference....
Medicine Products: